Chronic Myelogenous Leukemia (NCT03106779)
A Phase III, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors.
|This study is recruiting: Phase III||Actual Start Date: [October 26, 2017]||Estimated Completion Date: [March 19, 2025]||Novartis Reference Number: CABL001A2301|
|Condition: Chronic Myelogenous Leukemia in Chronic Phase||Interventions: asciminib, bosutinib||Estimated Enrollment: [222 participants]||ClinicalTrials.gov Identifier: NCT03106779|
|This study is recruiting: Phase III||Actual Start Date: [October 26, 2017]|
|Estimated Completion Date: [March 19, 2025]||Novartis Reference Number: CABL001A2301|
|Condition: Chronic Myelogenous Leukemia in Chronic Phase||Interventions: asciminib, bosutinib|
|Estimated Enrollment: [222 participants]||ClinicalTrials.gov Identifier: NCT03106779|
The purpose of this pivotal study is to compare the efficacy of ABL001 with that of bosutinib in the treatment of patients with CML-CP having previously been treated with a minimum of two prior ATP-binding site TKIs with BCR-ABL ratios ≥ 1% IS at screening.
Participants may be eligible to participate if they:
- Are 18 years or older
- Confirmed diagnosis of CML-CP
- Prior treatment with a minimum of 2 prior ATP-binding site TKIs (i.e. imatinib, nilotinib, dasatinib, radotinib or ponatinib)
- BCR-ABL1 ratio ≥ 1% IS
- Meet other eligibility criteria
Find a Trial Site Location
To find a list of all our recruiting site locations, enter your address below.
Still Have a Question?
Are you a Patient or Caregiver looking for more information?
Are you a Health Care Professional looking for more information?
To view eligibility requirements for this trial, arms and interventions, trial sites and study design, please click to visit this trial on www.clinicaltrials.gov.
Other chronic myelogenous leukemia trials you might be interested in:
A Phase II, Multicenter, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
BCR-ABL1 - Breakpoint cluster region-Abelson murine leukemia, CML-CP - Chronic Myelogenous Leukemia in Chronic Phase
Last Updated: May 1, 2019